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On the middle ground between open source and
commercial software - the case of the Newbler
program
Alexander J Nederbragt
Earlier this year, I started a petition (http://flxlexblog.
wordpress.com/2014/01/31/make-newbler-open-source/)
to ask Roche Applied Science to make the source code
of their Newbler software (GS De Novo Assembler, GS
Reference Mapper and GS Amplicon Variant Analyzer)
open source. In this column, I want to explain my mo-
tivation, describe my interactions with Roche, and place
this petition in the wider perspective of closed- versus
open-source software.
First, I am a software user, not a developer. I do write
code, but more in the form of scripts to tie existing pieces
of software together, or to analyze and compare results
from different programs. I have a policy of using open-
source software for my scientific work. I am a firm be-
liever in the importance of reproducibility in science, and
the openness and transparency of open-source software
are crucial for this. ’Non-availability of code [is] a serious
impediment to reproducibility’ [1].
One of the exceptions to my rule of only using open-
source software in my research is my use of the Newbler
program. This software is developed and maintained by
454 Life Science, a Roche company. Newbler’s purpose is
the analysis of data coming from the 454 GS FLX and GS
Junior sequencing machines sold by 454 through Roche.
Newbler is closed source. However, it is not a strictly com-
mercial program as it is distributed without cost to anyone
who asks (by submitting a form through http://454.com/
contact-us/software-request.asp). It is a free program, but
‘free’ as in ‘for no cost’ (like ‘free beer’), not as in 'free
speech' (see https://www.gnu.org/philosophy/open-source-
misses-the-point.html).
In my experience, Newbler is one of the best programs
for working with 454 data and it has been used for many
large and small genome assemblies. For example, we
used it successfully for assembling the first genome as-
sembly of Atlantic cod [2]. I am such a fan of the pro-
gram that I even wrote a user-focused manual for it
(available at https://contig.wordpress.com).
I feel the fact that Newbler is not open source has ham-
pered its use among scientists. Although I have no direct
evidence for this statement, it is a fact that a number of
studies that have compared programs for the assembly of
sequencing data, such as GAGE (http://gage.cbcb.umd.
edu/assemblers/index.html) and GAGE-B (http://ccb.jhu.
edu/gage_b/genomeAssemblers/index.html) did not in-
clude the Newbler program. Nevertheless, Newbler scored
very well in a competition in which outsiders could submit
assemblies (assemblathon2 [http://www.gigasciencejournal.
com/content/2/1/10]). Newbler is also one of the
few programs that can handle data from multiple technolo-
gies for so-called hybrid assembly. Newbler can even as-
semble human genomes, as the company demonstrated
in 2013 (http://www.roche.com/media/media_releases/
med_dia_2013-02-22.htm).
I started the petition to ask Roche to make Newbler
open source for the following reasons:
1) Only open-source software allows for transparent
reproducibility in science, so a widely used program
such as Newbler should be open source
2) In October 2013, Roche announced it will shutdown
its 454 sequencing business in mid-2016 (http://
www.genomeweb.com/sequencing/roche-shutting-
down-454-sequencing-business); this announcement
led me to worry that Newbler could disappear too
3) The value of Newbler would be much greater if
researchers could learn how the program works, and
perhaps even improve upon it.
In just two weeks, 162 people signed the petition (see
http://figshare.com/articles/Petition_make_Newbler_open_
source/936937), many more than I anticipated. In the mean
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time, I had contacted Roche and they agreed to let me
hand over the petition during the Advances in Genome
Biology and Technology (AGBT) meeting in Florida on
February 13th this year. I had an open and constructive
dialogue with the head of the Roche Sequencing unit and
the vice president of the Roche 454 sequencing business.
Roche clearly appreciated the petition initiative, and the
strong signal that was sent through it. I was promised an
official response, which I subsequently received and
posted on my blog (http://flxlexblog.wordpress.com/2014/
03/17/make-newbler-open-source-the-roche-response-and-
the-future-of-newbler/). The response boils down to this:
the Newbler software will be available after the 454 shut-
down, free of charge as before, but Roche will not make
the code open source. Roche intends to integrate it into
their future sequencing platforms (they surely are working
on something, alone or with a partner).
My interaction with Roche was very positive and, in a
way, their response was reassuring: Newbler will not dis-
appear. Unfortunately, we did not achieve what the
signees and I hoped for: Newbler will remain closed
source. This was of course a disappointment. In all fair-
ness, however, Roche’s position is understandable. They
have invested, and continue to invest, in this software,
which gives their platform a competitive advantage. Re-
leasing the code will give at least one of their competi-
tors (IonTorrent/Thermo Fisher Scientific) an advantage
as it sells instruments - the Ion Torrent PGM and
Proton - that produce a similar type of data.
It is interesting to note that Newbler is positioned in the
middle between commercial, closed-access and open-
source software. There is no fee for using it, which makes
it very accessible and provides it with a clear advantage
over commercial software. Nevertheless, Newbler suffers
from many of the disadvantages of closed-source software:
these are black boxes, with little to no insight available
into the algorithms behind them or their inner workings.
There are no peer-reviewed papers describing them. Old
versions are often not available, hampering reproducibility.
If the company decides to pull the software off the market,
or to remove a feature that is important for some re-
searchers’ work, there is nothing that can be done. The
closed-source, no-fee model has another potential prob-
lem, as there may not be an incentive for the company to
provide support for the software. Luckily, this seems not
to be the case for Newbler; Roche says that they record all
bug reports and feature requests, and take these very ser-
iously during development of the next version. There is,
however, no transparency: their bug and feature trackers
are as closed as the source code.
Interestingly, other companies who sell sequencing instru-
ments have made important parts of the software they
produce open source. Worth mentioning are Pacific Biosci-
ences’ SMRT Analysis package (www.pacbiodevnet.com and
https://github.com/PacificBiosciences), Thermo Scientific’s
Ion Torrent mapping and variant calling software (https://
github.com/iontorrent) and Illumina’s ISAAC aligner
(https://github.com/sequencing). These companies clearly
believe in the benefits of open-source software as part of
their business model.
There will always be a market for commercial soft-
ware, because of its ease of use and sometimes because
it is just plainly better. I am a strong believer in open-
access software, and I believe this model has a bright fu-
ture. Good, closed-source but free programs such as
Newbler, which are in the middle of these two extremes,
will surely have a user base. But Roche have missed a
huge opportunity by not making Newbler a true open-
source software. Not charging for closed-access software
does not necessarily make it better than commercial
software.
By the way, the petition to convince Roche to make
Newbler open source is still open, feel free to add your
signature! (https://docs.google.com/spreadsheet/viewform?
formkey=dHRvZDFUcldvZXVnWmhvSnlMWDBLQ1E6MA).
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